Haïk S, Brandel J P, Salomon D, Sazdovitch V, Delasnerie-Lauprêtre N, Laplanche J L, Faucheux B A, Soubrié C, Boher E, Belorgey C, Hauw J J, Alpérovitch A
Raymond Escourolle Neuropathology Laboratory, INSERM U360, Salpêtrière Hospital, 47, bd de l'Hôpital, 75651 Paris Cedex 13, France.
Neurology. 2004 Dec 28;63(12):2413-5. doi: 10.1212/01.wnl.0000148596.15681.4d.
Quinacrine has been reported as an antiprion agent and proposed as an immediately applicable treatment for Creutzfeldt-Jakob disease (CJD). The authors report the results of an open compassionate procedure to which 32 CJD patients had access. In some genotypic subgroups, a slight but nonsignificant increase in survival was observed, likely due to biased inclusion of long-term surviving patients. There was no pathologic evidence of a beneficial effect of quinacrine treatment.
已有报道称喹吖因是一种抗朊病毒剂，并被提议作为克雅氏病（CJD）的一种可立即应用的治疗方法。作者报告了一项开放的同情性治疗程序的结果，32例CJD患者参与了该程序。在一些基因亚组中，观察到生存期有轻微但不显著的延长，这可能是由于偏向纳入了长期存活的患者。没有病理学证据表明喹吖因治疗有有益效果。
